Amicus Therapeutics

Amicus Therapeutics, Inc.
TypeSubsidiary
Nasdaq: FOLD
Russell 2000 component
IndustryBiotechnology
FoundedFebruary 4, 2002 (2002-02-04)
Headquarters,
United States
Key people
Revenue
  • Increase $91,245,000 (2018)
  • Increase $36,930,000 (2017)
  • Increase ($328,777,000) (2018)
  • Decrease ($441,985,000) (2017)
  • Increase ($349,089,000) (2018)
  • Decrease ($449,121,000) (2017)
Total assets
  • Increase $789,951,000 (2018)
  • Decrease $627,024,000 (2017)
Total equity
  • Decrease $342,912,000 (2018)
  • Decrease $352,850,000 (2017)
Number of employees
508 (31 Dec 2018)
Websitewww.amicusrx.com
Footnotes

Amicus Therapeutics, Inc. is an American biopharmaceutical company based in Princeton, New Jersey. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates. As of April 2026, Amicus Therapeutics is a subsidiary of BioMarin Pharmaceutical.